Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Receivables: 2016-2025

Historic Receivables for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $233.9 million.

  • Collegium Pharmaceutical's Receivables rose 2.40% to $233.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $929.2 million, marking a year-over-year increase of 21.22%. This contributed to the annual value of $253.5 million for FY2024, which is 41.23% up from last year.
  • Per Collegium Pharmaceutical's latest filing, its Receivables stood at $233.9 million for Q3 2025, which was up 9.82% from $213.0 million recorded in Q2 2025.
  • Collegium Pharmaceutical's 5-year Receivables high stood at $253.5 million for Q4 2024, and its period low was $90.1 million during Q2 2021.
  • Over the past 3 years, Collegium Pharmaceutical's median Receivables value was $183.9 million (recorded in 2024), while the average stood at $202.2 million.
  • In the last 5 years, Collegium Pharmaceutical's Receivables soared by 119.21% in 2022 and then dropped by 15.20% in 2023.
  • Over the past 5 years, Collegium Pharmaceutical's Receivables (Quarterly) stood at $105.8 million in 2021, then skyrocketed by 73.01% to $183.1 million in 2022, then declined by 1.96% to $179.5 million in 2023, then skyrocketed by 41.23% to $253.5 million in 2024, then increased by 2.40% to $233.9 million in 2025.
  • Its Receivables was $233.9 million in Q3 2025, compared to $213.0 million in Q2 2025 and $228.7 million in Q1 2025.